MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Smith & Nephew hires new finance chief as quarterly revenue rises

ALN

Smith & Nephew PLC on Thursday said it appointed a successor to outgoing Chief Financial Officer Anne-Francoise Nesmes.

It also said revenue increased 8.8% in the third quarter, and proclaimed an optimistic outlook for the full year.

The London-based medical technology company, which previously announced in August that Nesmes was to leave, has now appointed John Rogers as her successor.

Smith & Nephew said Rogers will join as CFO-designate on December 1 and following a period of induction, will join the board as CFO in the first quarter of 2024.

Rogers was most recently CFO at WPP PLC, Smith & Nephew noted, where he ‘successfully led the implementation of their global transformation programme’. This was after serving as CFO at J Sainsbury PLC.

‘John is a highly regarded chief financial officer with a proven track record operating around the world and across a number of industry sectors. His extensive experience in transformation and capital markets is especially important given Smith & Nephew’s focus on driving greater shareholder value,’ said Chair Rupert Soames.

Smith & Nephew also updated on its third quarter performance. It said revenue rose 8.8% to $1.36 billion from $1.25 billion a year earlier, representing underlying revenue growth of 7.7% and reported growth of 8.5% including an 80 basis point foreign exchange tailwind.

Orthopaedics revenue was up 8.3%, which it said was partly due to product launches and strategy improvements driving higher growth from Trauma & Extremities. Sports Medicine & ENT revenue was up 11%, with Smith & Nephew noting continued growth across most markets offsetting weakness in China.

Meanwhile, Advanced Wound Management revenue was up 3.6%, with double-digit growth from Smith & Nephew’s negative pressure portfolio but a slower quarter from Advanced Wound Bioactives.

Looking ahead, it expects full-year 2023 underlying revenue growth to be towards the higher end of the guidance range of 6.0% to 7.0%. Its trading profit margin is now expected to be around 18%, reflecting headwinds from China.

Shares in Smith & Nephew were up 4.3% to 962.60 pence each in London on Thursday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved.